Across TCGA pan-cancer cohorts, HOXB2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HOXB2 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HOXB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HOXB2 expression acts as an unfavorable survival marker.
LUAD are the cancer types where HOXB2 Mutation most reproducibly stratifies survival.